1.

正在开展的NSCLC脑转移ICIs联合疗法的临床试验

Summary of ongoing trials combining ICIs and other therapies for patients with NSCLC brain metastases

Category	NCT Identifier	Drug arms	Phase
ICIs: immune checkpoint inhibitors; NSCLC: non-small cell lung cancer; CT: chemotherapy; RT: radiation therapy; SRS: stereotactic radiosurgery; WBRT: whole brain radiation therapy; IDO: indoleamine-pyrrole 2, 3-dioxygenase; PD-L1: programmed cell death protein ligand-1.
ICI+CT	03526900	atezolizumab+carboplatin+pemetrexed	Ⅱ
ICIs+RT	02978404	nivolumab+SRS (15 Gy-20 Gy in 1 fraction)	Ⅱ
	02858869	pembrolizumab+SRS (6 Gy vs 9 Gy vs 18 Gy-21 Gy)	Ⅰ
	02696993	nivolumab+SRS vs nivolumab+WBRT vs nivolumab+ipilimumab+SRS vs nivolumab+ipilimumab+WBRT	Ⅰ, Ⅱ
ICI+anti-VEGF antibody	02681549	pembrolizumab+bevacizumab	Ⅱ
ICI+anti-IDO-1 agent	03343613	LY3381916 (anti-IDO-1 agent)+LY3300054 (anti-PD-L1 antibody)	Ⅰ